Amlate

Amlodipine

Method of action: Antianginal, Antihypertensive, Antispasmodic, Hypotensive, Vasodilator

Treatment option: Hypertension, Angina Pectoris, Prinzmetal Angina

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlate

Amlate is a prescription-only synthetic medication whose active ingredient is Amlodipine, which is typically formulated as Amlodipine besylate.

Property	Description
Active ingredient	Amlodipine (besylate)
Form	Oral tablet, solution, or suspension
Pharmacological class	Dihydropyridine Calcium Channel Blocker (CCB)
General purpose	Lowering blood pressure and relieving angina
Origin	Synthetic organic small molecule

What Type of Medicine is Amlate, and What is its Composition?

Amlodipine is classified as a long-acting Calcium Channel Blocker (CCB) of the dihydropyridine subgroup. This compound is the single core active ingredient, is synthesized, and is restricted to prescription-only (Rx) status. The medication is commonly prepared as an oral tablet, though its availability in liquid forms such as oral solution or suspension is a feature that supports its use across patient groups who may have difficulty swallowing solid forms.

Amlodipine: Classification as a Dihydropyridine CCB

The fundamental action of Amlodipine is rooted in its ability to selectively inhibit the movement of calcium ions across the walls of muscle cells within the body’s peripheral blood vessels. Amlodipine works by targeting L-type calcium channels, distinguishing it from other CCBs by its preferential action on the vascular smooth muscle. This targeted approach allows it to function primarily as a potent blood vessel widener, offering a specialized method for managing vascular conditions.

Summary of General Therapeutic Purpose and Action Type

The overall function of Amlate is that of a powerful long-acting vasodilator and antihypertensive agent. The core benefit is achieved by this relaxation and widening of blood vessels, which significantly reduces peripheral vascular resistance and helps lower high blood pressure. Its inclusion on the WHO Model List of Essential Medicines signifies its established global importance for treating hypertension and angina. The compound's extended half-life supports a convenient single daily dosing regimen to maintain consistent therapeutic control.

Regulatory References

WHO Model List of Essential Medicines

What side effects are possible with Amlate?

Amlate's (Amlodipine) safety profile is defined by official regulatory documentation, which classifies potential effects by frequency and the body system affected.

Adverse Reaction Classification

The most frequently reported adverse event is peripheral edema (swelling of the ankles or feet), which is classified as Very Common (10%). Other Common (1% to 10%) effects are typically associated with the drug’s vasodilating action and include headache, dizziness, flushing, fatigue, palpitations, somnolence (drowsiness), abdominal pain, and nausea.

Effects are grouped by System-Organ Class, with reports spanning Nervous System Disorders (dizziness, somnol), Vascular Disorders (flushing), and Gastrointestinal Disorders (abdominal pain). Uncommon (0.1% to 1%) events include insomnia, tremor, hypotension, and rash.

Serious Safety Considerations

Serious Adverse Reactions are rare but are officially documented, including angioedema (swelling of the face or throat), hepatitis, jaundice, significant liver enzyme elevations, and, very rarely, myocardial infarction or serious arrhythmias.

Population-Specific Safety Notes

The official label includes specific notes for populations where drug exposure may be altered. Older adults and individuals with hepatic (liver) impairment may experience decreased clearance, which typically requires careful monitoring. Additionally, the incidence of edema is documented as being dose-related, and effects like headache and flushing may be more apparent at the initiation of treatment.

Use is contraindicated in patients with severe hypotension (very low blood pressure) and cardiogenic shock, as well as in individuals with known hypersensitivity to this class of medication.

Overdose and Emergency Response

Amlate overdose is primarily characterized by the exaggerated effects of its pharmacological class, specifically excessive peripheral vasodilatation. This physiological response leads to profound hypotension, which is a marked and potentially prolonged drop in systemic blood pressure. Other documented manifestations can include a compensatory reflex tachycardia. Severe outcomes are cited in regulatory documents, including the potential for circulatory collapse and the development of shock, which is recognized as carrying a risk of fatal outcome.

Due to the severity of these documented manifestations, immediate emergency medical attention must be sought upon suspicion of overexposure. Official regulatory guidance mandates that active cardiac and respiratory monitoring be initiated at once, alongside frequent blood pressure measurements. Treatment relies entirely on symptomatic and supportive measures; no specific antidote is known for this medication's overdose. Supportive management involves providing active cardiovascular support, including the elevation of extremities, and the judicious use of vasopressors if the profound hypotension is unresponsive to initial conservative measures. Because Amlodipine is highly protein bound, official documents state that hemodialysis is not likely to be of benefit in removing the drug. An overnight hospital stay for observation may be required following initial stabilization.

Therapeutic Uses of Amlate

What Amlate Treats: Main Uses and Benefits

Amlate is commonly used across conditions presenting with systemic or localized discomfort, primarily serving as supportive therapy for conditions marked by increased physiological stress. Its use is established for managing hypertension (high blood pressure) and various forms of angina pectoris (chest pain).

The medication is applied across therapeutic domains involving distressing symptoms, including the long-term control of blood pressure and the management of anginal pain in chronic stable angina and vasospastic angina. It is also relevant across conditions presenting with systemic or localized discomfort, such as established Coronary Artery Disease (CAD).

The primary therapeutic benefit generally involves sustained control over elevated arterial pressure and may include a reduction in the frequency and severity of chest pain episodes. This supportive relief assists with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Symptom Management for Anginal Chest Pain and High Blood Pressure

The medication plays a role in managing symptoms that may appear suddenly or fluctuate. It contributes to improved day-to-day comfort and may assist with reducing the risk of future acute or disruptive episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Amlate?

Amlate (Amlodipine) is approved for use in adults for all labeled indications. Pediatric use is established only for the treatment of hypertension in children aged 6 to 17 years. Use in children under 6 years of age is not established according to regulatory labeling.

Contraindications: Populations Who Must Not Use Amlate

The medicine is formally contraindicated in patients with a known hypersensitivity to amlodipine, any dihydropyridine derivative, or any excipients in the formulation. It must also not be used in patients presenting with severe hypotension, a state of shock (including cardiogenic shock), or significant obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis).

Restricted and Conditional Use

Specific caution and careful management are required for certain populations. Patients with hepatic impairment (liver disease) should be monitored closely, as the drug's clearance is decreased. Older adults and small patients may require a lower initial dose. Use in patients with congestive heart failure requires caution, as regulatory data suggests a potential increase in the risk of future cardiovascular events.

Pregnancy and Lactation Eligibility Status

The safety of Amlate during pregnancy is not established in humans; use is permitted only if the benefit is determined to outweigh the risk, and no safer alternative is available. Use is not recommended during breastfeeding due to the medicine's excretion into human milk.

What should I know about interactions with other medicines?

The interaction profile for Amlate (Amlodipine) is structured by documented pharmacokinetic and pharmacodynamic influences, as established in government regulatory labeling.

Interactions with Other Medicines

Co-administration with strong or moderate CYP3A4 inhibitors, such as certain antifungals or macrolide antibiotics like clarithromycin, may result in a significant increase in amlodipine systemic exposure. Conversely, medicines or substances classified as CYP3A4 inducers (e.g., rifampicin or St. John's Wort) may lead to a reduction in plasma concentrations.

Amlodipine has a significant documented interaction with Simvastatin. Due to Amlodipine increasing the exposure of Simvastatin, the regulatory restriction specifies that the Simvastatin dose must be limited to a maximum of 20 mg daily when these two agents are taken together. Amlodipine also carries a documented risk of increased blood levels of certain immunosuppressants, including Tacrolimus and Cyclosporine, necessitating close monitoring.

Mechanism of Action

Cellular Action and Smooth Muscle Relaxation

Amlate initiates its action as an inhibitor of the L-type Voltage-Gated Calcium Channels (CaV1.2) . These channels are situated primarily on the cell membranes of vascular smooth muscle cells. The drug's interaction with this target stops the essential influx of calcium ions into the cell's interior. Since the movement of calcium is required for muscle contraction, limiting its availability disrupts the molecular signal, resulting in the relaxation of the arterial walls.

Pathway Modulation and Vascular Widening

This cellular relaxation disrupts the excitation-contraction coupling pathway, reducing the overall tone of the arteries. Classified as a peripheral action, this process facilitates vasodilation (widening) of both the peripheral and coronary arteries. This widening results in a decrease in Systemic Vascular Resistance (SVR), which is the resistance against blood flow throughout the body, and simultaneously produces an increase in blood flow to the heart muscle. These physiological changes constitute the drug's core pharmacodynamic mechanism.

Dosage and Administration Information

Amlate is officially administered via the oral route and is available as a tablet in strengths of 2.5 mg, 5 mg, and 10 mg, or as an oral liquid formulation. The therapy is structured as a once-daily regimen and is permitted to be taken with or without food, a condition supporting consistent administration.

The standard initial dose for adults managing approved indications is 5 mg once daily, progressing to a maintenance range between 5 mg and the maximum permitted dose of 10 mg daily. Dosage adjustments are required to be gradual; the official protocol specifies a minimum waiting period of 7 to 14 days between dose increases to allow the medication to reach a stable therapeutic level before evaluating the response.

Usage is modified for specific populations. Older adults and those with hepatic impairment are typically started on a reduced dose of 2.5 mg once daily. For children aged 6 to 17, the maximum dose permitted is strictly 5 mg per day. If a dose is missed, the instruction is to take it as soon as remembered unless it is nearly time for the next scheduled dose, ensuring the intended once-daily pattern is maintained.

Recent Clinical Evidence

Research evidence / Overview of studies for Amlate

Conditions Characterized by Fluctuating and Episodic Manifestations

Research examined Amlate in the context of conditions characterized by fluctuating or episodic manifestations. The studies was conducted in clinical trials and observational settings examining patient-reported experiences. These studies generally focused on periods of heightened symptom activity and conditions where symptoms may vary in intensity.

The research monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. Research examined short-term symptom changes. The data suggest patterns related to certain changes in patient-reported outcomes describing perceived discomfort during periods of fluctuating or unstable symptoms. The findings indicate that the changes measured primarily occurred over defined, shorter time intervals.

It is important to understand that this research mainly covers short-term or episodic symptom patterns. It is not yet clear how Amlate may influence the overall progression of conditions presenting with cycles of stability and flare-ups. Follow-up durations were limited in many key studies, meaning the data available contributes to understanding short-term changes, but long-term effects are not fully established.

Short-Term Symptom Changes in Observed Populations

The studies were observed in a variety of research settings, ranging from formal clinical trials to more open-ended observational studies evaluating daily-life functioning. These research scenarios focused on studies conducted during periods of increased symptom activity and studies exploring short-term symptom changes. The research was conducted by studies to contribute to understanding symptom intensity or variability.

Overall, the data show patterns related to how outcomes reflecting daily functioning or activity level evolved over the measured timeframes. The research highlights changes measured during the study period in these specific groups. However, certainty remains low when trying to generalize these findings broadly. Comparative evidence is lacking in some areas, which means it is difficult to directly compare the findings of Amlate with all relevant approaches using the existing body of research.

Studies help show what has been observed so far in the group of patients who participated in the research. Findings describe group patterns, not personal outcomes, and it is important to remember that research provides context but not individual predictions.

Subgroup Findings for Specific Demographics

Research examined the use of Amlate in certain population groups, such as younger adults and patients with certain co-existing health conditions. Research was conducted to explore if the patterns observed in the general study population held true for these more specific groups.

For these populations, subgroup findings are uncertain. The main limitation is that data for certain groups remain insufficient because sample sizes were modest in the studies focused on these demographics. The results apply only to the populations studied, meaning if a specific demographic was not included, there is no evidence to describe how Amlate may impact them. Research in this area is ongoing to provide more insight, but for now, the available evidence quality varies across studies for special populations.

Frequently Asked Questions (FAQ)

Common questions about Amlate (FAQ)

Q: Does Amlate interact with caffeine or alcohol?

Official regulatory documents indicate that consuming alcohol while taking Amlate may cause additive blood pressure-lowering effects. This could increase the likelihood of experiencing symptoms such as dizziness or lightheadedness. There is no specific regulatory warning or documented interaction regarding the use of caffeine.

Q: How long can a person usually expect to take Amlate?

Amlate is officially indicated for the treatment of hypertension (high blood pressure) and certain types of angina (chest pain). Since these conditions are typically chronic (long-term) in nature, regulatory guidelines suggest that the use of Amlate may be expected to be ongoing for extended periods.

Q: Does Amlate have a risk of dependence or addiction?

Official product information, as reviewed by regulatory agencies, does not classify Amlate as a controlled substance. The documents also do not include specific warnings regarding a risk of drug dependence or addictive behavior associated with its use.

Q: Can Amlate be used by people with kidney issues?

According to official regulatory data, significant kidney impairment (renal impairment) typically does not impact the body's clearance or processing of Amlate. This indicates that dose adjustments are typically not necessary for kidney issues alone, according to regulatory data.

Q: Why do some people say Amlate is hard to stop taking?

Regulatory guidance for this type of medication advises patients against abruptly stopping therapy. Suddenly discontinuing the drug may cause the underlying condition it is treating—such as high blood pressure or chest pain—to return or potentially worsen. Consultation with a healthcare provider is generally part of the cessation process for this type of medication.

Q: Is there a generic version of Amlate available?

Yes, the active ingredient in Amlate, Amlodipine, is available in generic formulations. Regulatory bodies, such as the FDA, authorize these generic versions only after they have demonstrated bioequivalence to the brand-name product.

Q: Does Amlate affect fertility or reproductive health?

Studies conducted in male rats have shown that Amlodipine may cause impairment of fertility in those animals. There are no available human data to describe whether Amlodipine impacts fertility in women.

Q: What is the process for monitoring the effects of Amlate?

Official information indicates that close monitoring is required for patients with hepatic impairment (liver disease) due to decreased drug clearance. Additionally, close surveillance may be required when Amlate is combined with certain interacting medications. The official documentation does not specify a universal, routine testing process for all patients.

Q: Is it necessary to have routine tests while taking Amlate?

For patients with hepatic (liver) impairment, official regulatory materials advise periodic monitoring of liver function. However, for patients without specific risks or interacting medications, routine bloodwork or specific universal tests are not mandated in the official prescribing information.

Q: Does Amlate cause weight gain or weight loss?

Official reports of adverse effects list both weight gain and weight decrease as events that have been reported by users. Neither of these effects is classified as a common side effect of the medicine.

Q: If I switch to a generic version, will the effects be the same as brand-name Amlate?

Regulatory bodies require generic drug manufacturers to prove that their product meets strict bioequivalence standards. This means the generic must deliver the same amount of the active ingredient into the bloodstream over the same time period as the brand-name version to establish that the therapeutic effects should be consistent.

How should Amlate be stored and disposed of?

Storage Conditions

Amlate (amlodipine besylate) must be stored at controlled room temperature, which is between 15 C and 30 C (59 F and 86 F). The product requires mandatory protection from light and moisture to maintain its stability and must be kept in a tight, light-resistant container, according to regulatory standards. Do not store the medication above this temperature range, and refrigeration or freezing is typically excluded by the required conditions.

Handling and Disposal

The medicine must be stored securely out of the sight and reach of children.

Disposal of any unused or expired Amlate must be done in accordance with local requirements. The product is not included on the FDA's flush list. Proper disposal involves authorized medicine take-back programs or safe household trash disposal methods, with instructions to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.